Introduction
Convulsive Status Epilepticus (CSE) is a life-threatening neurological emergency with patients presenting with recurrent seizure activity. Swift medical management is required to prevent progression to Convulsive Refractory Status Epilepticus (CRSE) and the associated high rates of mortality and morbidity. The current International League against Epilepsy (ILEA) definition of CSE is a 'condition in which epileptic activity persists for 30 min or more, causing a wide spectrum of clinical symptoms, and with a highly variable pathophysiological, anatomical and aetiological basis'. 1 Thirty minutes has been acknowledged as the minimum duration of time necessary for neuronal injury to occur. 2, 3 Animal models have shown that in CSE there is endocytosis of inhibitory gamma-aminobutyric acid (GABA A ), causing a reduction of GABA A at the synaptic membrane. This leads to GABA A inactivity. The movement of excitatory N-methyl-D-aspartic acid (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) to the synaptic membrane during the initial stage of a seizure leads to the development of further excitatory receptors causing the progression from isolated seizures to CSE. 4 In adults the frequent causes of CSE are cerebrovascular disease, drugs and metabolic disturbances. 5 Only 20% of adult patients have had a prior neurological complaint. Acute brain injury usually leads to new cases of CSE. 6 CRSE has been labelled as CSE which is not controlled after treatment with a minimum of two first-line anti-epileptic drugs (AED) or CSE persisting greater than 2 h without recovery despite treatment. 7 One multicentre study showed that 45% of cases progressed to CRSE. 8 The National Institute for Health and Care Excellence (NICE) (2012) have provided a protocol for the management of CRSE and two points to note are: (1) care should be shared between the anaesthetist and neurologist (2) continuous electroencephalogram (EEG) monitoring is necessary for CRSE. 9 This protocol replicates the guidelines provided by NICE in 2004.
Convulsive Refractory Status Epilepticus management
The recommended treatment for terminating CSE is a benzodiazepine such as lorazepam or diazepam followed by phenytoin, fospheytoin or phenobarbital. 9 The continuation of seizure activity with resistance to at least two AEDs is regarded as refractory, requiring intensive care unit (ICU) input. Currently continuous EEG monitoring in conjunction with an intravenous (IV) anaesthetic infusion of midazolam, propofol or thiopental sodium is recommended by NICE. The justification for anaesthesia use in treatment of CRSE is that brain damage is a consequence of continuous electrographic seizure activity and the intention is to see a lack of high frequency periods on the EEG known as burst suppression. 10 Traditionally AEDs are withdrawn after burst suppression has been achieved for at least 24 h 11 although insufficient data is available to propose that burst suppression is necessary to manage or avert seizure recurrence. 13 Without continuous EEG monitoring the treating clinician cannot assess the development of burst suppression. This risks inappropriately excessive administration of anaesthetic agents, or the continuation of electrical status epilepticus with secondary deleterious injury to the brain. As a tertiary referral centre we noted very different practices within referring hospitals, particularly in the aspect of access to EEG monitoring, drug treatment and the involvement of neurology colleagues. We undertook a literature search but found no previous publications comparing the management of CRSE in adults in different acute trusts in the United Kingdom (UK).
Aims
We therefore undertook an audit with the following aims:
Establish current treatment practice for CRSE in ICU across the UK. Determine if NICE guidance for the management of CRSE is being followed.
Methods
A list of all 162 acute National Health Service (NHS) Trusts in the UK was identified and ordered alphabetically. A random starting point was selected using a random number generator corresponding to a trust on the list and every second trust thereafter was included. We then performed a systematic random selection of 75 trusts from this list. A brief questionnaire was then sent to the trust's patient advice and information services to be forwarded to the ICU team under the agreement of the Freedom of Information Act 2000. We asked respondents to answer five specific questions:
1. Is a management plan in place for CSE? 2. Is a protocol for early CSE available in ICU? 3. Do you involve neurologists at any stage of management in patients with CSE? 4. Is access to continuous EEG monitoring available? 5. Do you have a specific protocol if CRSE occurs?
We also asked each trust to send a copy of their protocol for CRSE if they had one available.
Results
The flowchart (see Fig. 1 ) shows the results received from the 75 acute trusts selected.
Fifty five (73%) trusts responded to the participation responders were either hospital managers, ICU nurses or ICU doctors. The reason for no response was later sought after in the other 20 trusts. Fifteen of these trusts did not reply on a second occasion. Four trusts were updating their protocols and were not able to enclose any information and one trust replied that they did not have the information to send.
The results of each questions asked in the audit are shown below.
Is a management plan in place for CSE?
Of the initial 55 respondents, 14 trusts had no management plan in place. Eight of these stated that they did not hold this information. Three trusts stated that they no longer treat or accept patients in an acute setting, two were updating their protocols and one trust did not follow recognised guidelines.
The initial CSE treatment in hospital was consistent across all 41 trusts with a management plan, stating that lorazepam 4 mg IV with a repeat dose after 10 min would be administered. Alternatively diazepam 10 mg would be used if indicated. All trusts would then use phenytoin between 15 and 20 mg/kg, however, the indicated time of use and dose of maintenance varied. Sixteen trusts would infuse IV phenytoin 20-40 min after CSE had begun and 13 trusts followed the NICE guidelines of between 0 and 60 min after CSE had been diagnosed. Eleven trusts did not state how long the time interval would be before phenytoin was administered with one trust simply stating on their protocol 'if seizures are not terminated phenytoin is used'. One trust would use this AED between 60 and 90 min after CSE.
Is a protocol for early CSE available in ICU?
The second question focused on the protocol for early CSE available in ICU. Thirty-one trusts had a protocol available of which 22 used their own guidelines but did not state who or when the guidelines had been designed. Six trusts used the NICE guidelines available in their ICU office. Two trusts followed their nearby acute trust protocol and one utilised the European Federation of Neurology guidelines. For the ten trusts with no guidelines available in ICU, seven stated that they would apply the NICE guidelines, two would follow the advanced life support directives and one trust stated they made use of the British National Formulary.
Do you involve neurologists at any stage of management in patients with CSE?
Next we assessed the neurological input into management and 23 trusts involved a neurologist at some stage of their treatment protocol. 13 followed the NICE guidelines which simply states that patients 'require care shared between the anaesthetist and the neurologist from an early stage'. Therefore it was not possible to determine when exactly the neurologist was involved. The remaining showed marked variability for referral. Three trusts would call the consultant neurologist as soon as CRSE had begun. Two trusts seeked a neurology consultant's review for all patients who were admitted to ICU with one of these trusts transferring the patient to a neurology unit as soon as the patient reached CSE. The remaining four stated that either neurologist input occurred after the first onset of seizure, after 10 min of seizure activity, 'early referral' and 'uncertain when to include a neurologist'. Eighteen of the trusts involved no neurological input within their protocol and 11 of these did not state who would assist the patient care and decision making. Three trusts contacted the on-call anaesthetist, three would get help from the ICU registrar or 'senior' and one trust were advised by the on-call medical doctor.
Is access to continuous EEG monitoring available?
When asked about EEG monitoring, which is stated as essential by NICE in the management protocol, 23 trusts did not indicate if EEG was a part of their protocol or if they had access to continuous EEG. Of the 18 trusts with access to EEG, 15 trusts would first use the equipment as soon as the patient was intubated and transferred to ICU. Two trusts would use the EEG as soon as general anaesthesia was given and one trust as soon as CRSE began.
Do you have a specific protocol if CRSE occurs?
The final question concentrated on the guidelines for CRSE. Only 21 trusts had any guidelines in place (see Fig. 2 ). 13 followed the NICE guidelines of a triple option of either propofol (1-2 mg/kg bolus, then 2-10 mg/kg/h), thiopental sodium (3-5 mg/kg bolus, then 3-5 mg/kg/h) or midazolam (0.1-0.2 mg/kg bolus, then 0.05-0.5 mg/kg/h). Four trusts employed the same option with no doses specified. Thiopental sodium was the first choice in four trusts with three using a dose of 4 mg and the other not specifying a dose. One trust utilised propofol 1-2 mg/kg and one stated using 'general anaesthesia' with no specific AED mentioned.
Looking at when anaesthetic management would be ended, 14 of the 21 trusts with guidelines for CRSE would continue treatment until a primary endpoint of EEG activity suppression was seen. Five simply replied that EEG would be used with no endpoint noted. Two trusts continued anaesthesia 12-24 h after seizure activity had ended. 
Discussion
The main strength of this study is that there is no previous published audit that has compared the management of adult CRSE amongst acute trusts in the UK. We have identified significant differences within the protocols which may cause delay in efficient treatment and put patients at risk of potential preventable harm. Of the 55 respondents, only 21 trusts have guidelines for CRSE management and 18 trusts use or have access to continuous EEG. Similar results of variation in management of CRSE were also shown in a European survey of epileptologists and critical care neurologists. 12 One limitation of this audit was the missing data from the nonresponding acute trusts. Twenty trusts did not respond and feedback from these non-respondents on the questionnaire style and layout may increase the response in any future audit. Questionnaires may also not reflect front line clinical practice. An additional drawback is that the questionnaire may not have captured the management strategies that are not included in the trust protocol.
Neurologists surprisingly may not be consulted in patient care or are included very late in the management plan despite CSE being a neurological emergency. A diagnostic problem is that as many as half of all patients presenting to hospital with SE have been found to not have epilepsy 13 with non-epileptic seizures (NES) commonly misdiagnosed. Admitting neurologists have been able to accurately predict such occurrences in 67% of cases 14 enhancing the argument for early neurologist input. The early use of EEG prior to ITU transfer can also help differentiate NES, as alpha waves between movement artefacts do not occur in CSE.
One major barrier to following NICE guidance on CRSE is limited local resources. The European Society of Intensive Care Medicine recommended continuous use of EEG for CRSE rather than intermittent use. 15 However, EEG monitoring may not be available in many trusts due to a lack of neurophysiological services. Similarly, a neurologist may not be involved because local expertise is unavailable. The ideal solution, in our view, would be for patients with CRSE to have early referral to a tertiary neuroscience centre, especially for super refractory cases or when the diagnosis is in doubt. Such centres can provide specialised neuro-intensive care experience, continuous EEG monitoring, specialist neurological advice and practical experience in managing CRSE. However with limited neurology ICU beds, other options include using a bispectral index score (BIS) to guide burst suppression therapy or limited channel EEG with four channel recordings, which has a 98% specificity for seizure detection. 16 There are many unanswered questions in the management of CRSE such as drug choice, drug dosage, time interval before providing anaesthetic treatment and the ratio for burst suppression. Unfortunately, there is limited evidence to answer these questions which may further promote inconsistency in management practice. Therefore the established best practice recommended by NICE finishes with the advice of continuous EEG monitoring and access to specialist neurological advice.
This audit highlighted the variation of CRSE management in the UK and we hope that this paper will stimulate local service development and improve standards. There is a need to review the management across all trusts in the UK and also internationally, with standardised practice potentially providing a significant step in optimising patient care and reducing the mortality and long term morbidity associated with CRSE.
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